Geneva Biotech market a portfolio of viral and nonviral DNA delivery systems that provide new and better ways to deliver DNA into cells. Our Sur Access consulting arm provides biotech investment advisory and due diligence, evaluating asset, pricing, and revenue potential for rare diseases.
Cooperation possibilities
Sur Access offers strategic partnerships for biotech investment due diligence, JCA readiness, and Swiss BAG price negotiations. We collaborate with investors and developers to evaluate revenue potential and secure market access for ATMPs and rare disease therapies.
https://www.sur-access.com/
- https://geneva-biotech.com/
- Send an email
- Alicia Del Pierro
